Trastuzumab deruxtecan (T-DXd) improves overall survival (OS), compared with trastuzumab emtansine (T-DM1), in patients with previously treated, HER2-positive, advanced breast cancer, according to ...

Background: In phase II and III studies, treatment with T-DM1 or with P + H + docetaxel has shown statistically significant increases in progression-free survival (PFS) and overall survival (OS) vs ...

T-DM1 is a combination of Herceptin, a drug commonly used to treat HER2-positive breast cancer, and an experimental drug called emtansine, or DM-1.

T-DM1 improved overall survival for heavily pretreated patients with HER2-positive breast cancer Peer-Reviewed Publication. American Association for Cancer Research ...

After a median follow-up of 8.4 years, the updated results showed statistically significant improvement in OS with T-DM1 versus trastuzumab (HR 0.66, 95% CI 0.51-0.87, P=0.003), and iDFS also ...

T-DM1 is a novel ADC that combines the humanized antibody trastuzumab and the potent antimicrotubule agent DM1 (derivative of maytansine) using a unique and highly stable linker. 1 T-DM1, with its ...

Dr Conte said: "Our study showed T-DM1 had a meaningful clinical effect after first-line pertuzumab. The length of time that patients lived on T-DM1 treatment without their disease getting worse ...

Women getting T-DM1 had 9.6 months of progression-free survival, the time between starting the treatment and the cancer getting worse again, compared with 6.4 months in the standard therapy group.

T-DM1, an drug antibody conjugate of trastuzumab and DM1, a cytotoxic agent, is active against metastatic HER2-positive breast cancer and in patients with residual disease after neoadjuvant HER2 ...

Roche said patients with an aggressive type of breast cancer lived longer after taking its experimental "armed antibody" drug without the disease worsening than those on a mix of GlaxoSmithKline ...